LIU Li 1,2,3 , SU Mingzhu 2,3,4 , ZHANG Jinxin 2,3,4 , FENG Yujia 2,3,4
  • 1. Cardiac Surgery Intensive Care Unit of Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, P. R. China;
  • 2. Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, P. R. China;
  • 3. NHC Key Lab of Health Economics and Policy Research, Jinan 250012, P. R. China;
  • 4. Center for Cancer Control and Policy Research (Shandong University), Jinan 250012, P. R. China;
SU Mingzhu, Email: sumingzhu@ sdu.edu.cn
Export PDF Favorites Scan Get Citation

Objective To systematically review the incidence of financial toxicity among cancer patients in China. Methods The Cochrane Library, Web of Science, PubMed, Embase, CINAHL, CNKI, and WanFang databases were searched to collect studies on the prevalence of financial toxicity among cancer patients in China from January 2016 to April 2023. Two reviewers independently screened the literature, extracted data, and assessed the risk of bias of the included studies. A meta-analysis was performed by using Stata 16.0 software. Results A total of 24 studies involving 8 799 participants were included. Meta-analysis results showed that the prevalence of financial toxicity among cancer patients was 67.4% (95%CI 60.9% to 74.0%) in China. The subgroup analysis showed that sex, educational level, type of medical insurance, cancer site and stage, the cut-off of the instrument, and region were all influential factors of financial toxicity among cancer patients. Conclusion Current evidence shows that high prevalence of financial toxicity among cancer patients. Due to the limited quantity and quality of the included studies, more high-quality studies are needed to verify the above conclusion.

Citation: LIU Li, SU Mingzhu, ZHANG Jinxin, FENG Yujia. The prevalence of financial toxicity based on comprehensive scores for financial toxicity in Chinese cancer patients: a meta-analysis. Chinese Journal of Evidence-Based Medicine, 2023, 23(11): 1269-1274. doi: 10.7507/1672-2531.202306083 Copy

  • Previous Article

    Risk prediction models for stroke-associated pneumonia: a systematic review
  • Next Article

    Efficacy and safety of immune checkpoint inhibitor and bevacizumab combined with chemotherapy in the first-line treatment of advanced wild-type non-squamous non-small cell lung cancer: a network meta-analysis